Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03737812
Recruitment Status : Active, not recruiting
First Posted : November 13, 2018
Last Update Posted : January 21, 2020
Sponsor:
Information provided by (Responsible Party):
AbbVie

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of elezanumab in subjects with progressive Multiple Sclerosis (PMS).

Condition or disease Intervention/treatment Phase
Multiple Sclerosis (MS) Drug: elezanumab Drug: placebo Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 121 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis
Actual Study Start Date : February 27, 2019
Estimated Primary Completion Date : September 17, 2020
Estimated Study Completion Date : October 1, 2021

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Placebo Comparator: Placebo
Participants randomized to receive double-blind placebo by intravenous infusion.
 Drug: placebo
solution for infusion
Experimental: Elezanumab Dose 1
Participants randomized to receive double-blind elezanumab Dose 1 by intravenous infusion.
 Drug: elezanumab
solution for infusion
Other Name: ABT-555
Experimental: Elezanumab Dose 2
Participants randomized to receive double-blind elezanumab Dose 2 by intravenous infusion.
 Drug: elezanumab
solution for infusion
Other Name: ABT-555


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Overall Response Score (ORS) at Week 52 [ Time Frame: Week 52 ]
    The ORS is a composite score derived from 4 components: Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg Test in the dominant hand (9HPT-D), and 9HPT in the non-dominant hand (9HPT-ND).


Secondary Outcome Measures :
  1. 12-week confirmed disability improvement response rate on the Expanded Disability Status Scale Plus (EDSS+) [ Time Frame: 52 weeks ]
    12-week confirmed disability improvement is defined as a patient who showed an improvement in the EDSS+ and maintained the improvement for at least 12 weeks during the treatment period 52-weeks. The EDSS+ is used to assess severity of symptoms of MS and includes the Timed 25 Foot Walk (T25FW), 9-Hole Peg test in either hand (9HPT), and EDSS.

  2. 12-week confirmed disability improvement response rate on Timed 25 Foot Walk (T25FW) [ Time Frame: 52 weeks ]
    12-week confirmed disability improvement is defined as a patient who showed an improvement in the EDSS+ and maintained the improvement for at least 12 weeks during the treatment period 52-weeks. The T25FW is a tool that evaluates mobility and leg function performance.

  3. 12-week confirmed disability improvement response rate on 9-Hole Peg Test in either hand (9HPT) [ Time Frame: 52 weeks ]
    12-week confirmed disability improvement is defined as a patient who showed an improvement in the EDSS+ and maintained the improvement for at least 12 weeks during the treatment period 52-weeks. The 9HPT is a tool that evaluates upper extremity function.

  4. 12-week confirmed disability improvement response rate on Expanded Disability Status Scale (EDSS) [ Time Frame: 52 weeks ]
    12-week confirmed disability improvement is defined as a patient who showed an improvement in the EDSS+ and maintained the improvement for at least 12 weeks during the treatment period 52-weeks. The EDSS is a tool for quantifying disability in multiple sclerosis and monitoring changes in the level of disability.

  5. 24-week confirmed disability improvement response rate on the Expanded Disability Status Scale Plus (EDSS+) [ Time Frame: 52 weeks ]
    24-week confirmed disability improvement is defined as a patient who showed an improvement in the EDSS+ and maintained the improvement for at least 24 weeks during the treatment period 52-weeks. The EDSS+ is used to assess severity of symptoms of MS and includes the Timed 25 Foot Walk (T25FW), 9-Hole Peg test in either hand (9HPT), and EDSS.

  6. 24-week confirmed disability improvement response rate on Timed 25 Foot Walk (T25FW) [ Time Frame: 52 weeks ]
    24-week confirmed disability improvement is defined as a patient who showed an improvement in the EDSS+ and maintained the improvement for at least 24 weeks during the treatment period 52-weeks. The T25FW is a tool that evaluates mobility and leg function performance.

  7. 24-week confirmed disability improvement response rate on 9-Hole Peg Test in either hand (9HPT) [ Time Frame: 52 weeks ]
    24-week confirmed disability improvement is defined as a patient who showed an improvement in the EDSS+ and maintained the improvement for at least 24 weeks during the treatment period 52-weeks. The 9HPT is a tool that evaluates upper extremity function.

  8. 24-week confirmed disability improvement response rate on Expanded Disability Status Scale (EDSS) [ Time Frame: 52 weeks ]
    24-week confirmed disability improvement is defined as a patient who showed an improvement in the EDSS+ and maintained the improvement for at least 24 weeks during the treatment period 52-weeks. The EDSS is a tool for quantifying disability in multiple sclerosis and monitoring changes in the level of disability.

  9. Overall Response Score (ORS) at Week 12 [ Time Frame: Week 12 ]
    The ORS is a composite score derived from 4 components: Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg Test in the dominant hand (9HPT-D), and 9HPT in the non-dominant hand (9HPT-ND).

  10. Overall Response Score (ORS) at Week 24 [ Time Frame: Week 24 ]
    The ORS is a composite score derived from 4 components: Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg Test in the dominant hand (9HPT-D), and 9HPT in the non-dominant hand (9HPT-ND).

  11. Overall Response Score (ORS) at Week 36 [ Time Frame: Week 36 ]
    The ORS is a composite score derived from 4 components: Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg Test in the dominant hand (9HPT-D), and 9HPT in the non-dominant hand (9HPT-ND).

  12. Time to first improvement on 12-week confirmed Expanded Disability Status Scale Plus (EDSS+) [ Time Frame: 52 weeks ]
    12-week confirmed disability improvement is defined as a patient who showed an improvement in the EDSS+ and maintained the improvement for at least 12 weeks during the treatment period 52-weeks. The EDSS+ is used to assess severity of symptoms of MS and includes the Timed 25 Foot Walk (T25FW), 9-Hole Peg test in either hand (9HPT), and EDSS.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject has diagnosis of primary-progressive multiple sclerosis (PPMS) or non-relapsing secondary-progressive multiple sclerosis (SPMS) and no relapses for at least 24 months
  • Subject has evidence of physical disability according to Expanded Disability Status Scale (EDSS) or Timed 25-Foot Walk (T25FW) or 9-Hole Peg Test

Exclusion Criteria:

  • Treatment with any of the following within the 6 months prior to Screening: natalizumab; cyclosporine; azathioprine; methotrexate; mycophenolate mofetil; intravenous immunoglobulin (IVIg); any interferon product; and intravenous (IV), oral, or intrathecal corticosteroids for the purposes of disease modification
  • Treatment with the following within 1 year prior to Screening: cyclophosphamide or alemtuzumab
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03737812


Locations
Show Show 38 study locations
Sponsors and Collaborators
AbbVie
Investigators
Layout table for investigator information
Study Director: AbbVie Inc. AbbVie
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for additonal information
Responsible Party: AbbVie
ClinicalTrials.gov Identifier: NCT03737812    
Other Study ID Numbers: M14-397
First Posted: November 13, 2018    Key Record Dates
Last Update Posted: January 21, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Analytic Code
Time Frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access Criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
URL: https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by AbbVie:
Progressive multiple sclerosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
 Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases